Advertisement SIPO Selects Renhuang For Intellectual Property Pilot Program - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

SIPO Selects Renhuang For Intellectual Property Pilot Program

Renhuang Pharmaceuticals, a developer, manufacturer and distributor of botanical products, bio-pharmaceuticals and traditional Chinese medicines (TCM), has been selected by China's State Intellectual Property Office (SIPO) to participate in a unique intellectual property (IP) pilot program.

SIPO said that as a high growth company with a focus on technology innovation and intellectual property, Renhuang was selected as one of a handful pharmaceutical companies from Heilongjiang province to enroll in the pilot program.

As a participant of the IP pilot program, Renhuang will receive guidance from the SIPO in creating, using, protecting and managing intellectual property to foster innovation while protecting proprietary trademarks, technologies, processes, and products. The primary goal of the two-year IP pilot program is to help improve China’s economic growth and international competitiveness by strengthening its patent and trademark system.

Shaoming Li, chairman and chief executive officer of Renhuang, said: “The selection process for the IP pilot program was competitive and we are pleased to be a part of this unique opportunity. Our business thrives on innovation and strong intellectual property protection is a core component of our long-term success, including maintaining our leadership in the Siberian Ginseng (Acanpathax) based product market.

“Over the years, Renhuang has taken important steps to develop and manage our intellectual property portfolio. We plan to capitalize on the vast opportunities provided by this pilot program to continue to expand our intellectual property to further strengthen our competitive position.”